Antipsychotics - Articles - Page 12

Using Antipsychotics Judiciously in Children

December 1, 2014

Glen R. Elliott, MD, PhD
Chief Psychiatrist and Medical Director Children’s Health Council, Palo Alto, CA. Clinical Professor (Affiliated), Stanford University School of Medicine, Division of Child and Adolescent Psychiatry.
Dr. Elliott has disclosed that he has no relevant relationshipt or financial interests in any commercial company pertaining to this educational activity.

Read about the appropriate use of antipsychotics to treat disorders in children and adolescents, in an interview with psychiatrist Glen R. Elliott, MD, PhD.

Dealing With Side Effects of SSRIs

May 1, 2014

Pavan Madan, MD

Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression and anxiety in children and adolescents, but they are associated with significant adverse effects (AEs). Studies have shown that up to 50% of kids experience side effects from SSRIs, depending on the sample size and the type of study.

Metabolic and Extrapyramidal Effects of Antipsychotics

May 1, 2014

Tamara Pringsheim, MD

Tamara Pringsheim, MD
Assistant Professor, Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences University of Calgary.
Dr. Pringsheim has disclosed that she has been a paid consultant to Teva Neuroscience, Allergan, and Shire Canada. The editors have reviewed this interview and found no evidence of bias in this educational activity.

Pharmacoepidemiologist Tamara Pringsheim, MD, describes strategies for dealing with metabolic, extrapyramidal, and hormonal side effects of antipsychotics.

Glutamate’s Role in Schizophrenia

March 1, 2014

Steve Balt, MD, MS

Steve Balt, MD, MS Board Member, The Carlat Report. In private practice in the San Francisco Bay area. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.

There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.

Lower Antipsychotic Use Linked to Better Outcomes

October 30, 2013

Section editor, Glen Spielmans, PhD

...

APA Warns Against Common Uses of Antipsychotics

October 1, 2013

In September, the American Psychiatric Association (APA) released a list of common, but potentially dangerous and inappropriate, uses for antipsychotics.

RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013

Glen Spielmans, PhD

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?

The Psychosis Prodrome

January 1, 2013

Rachel Loewy, PhD and Demian Rose, PhD, MD

Rachel Loewy, PhD Assistant adjunct professor, University of California, San Francisco Dr. Loewy has disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Demian Rose, PhD, MD Assistant clinical professor, University of California, San Francisco Dr. Rose hase disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene?

Atypical Antipsychotics: Where is the Science, Where is the Evidence?

January 1, 2013

P Ken Gillman, MBBS

P Ken Gillman, MBBS Director, Psychotropical (www.psychotropical.com), Bucasia, Queensland, Australia Dr. Gillman has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Any psychiatrist who has practiced during the last decade has probably written more than a few prescriptions for an atypical antipsychotic. But do these drugs provide any clear advantages over their predecessors?

Old Versus New Antipsychotics

January 1, 2013

Robert Rosenheck, MD

Robert Rosenheck, MD Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.

Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science.